Changzhou Qianhong Biopharma Co., Ltd.
千红制药
002550
Shenzhen Stock Exchange
Company Profile
1. Industry advantages The biopharmaceutical industry has become an important sector in China's national economy. Biopharmaceutical products have the characteristics of targeting and safety, as well as high technical barriers, and have become an important indicator of a country's modern biotechnology development level. The biopharmaceutical industry is one of the fastest-growing, most dynamic, and technologically advanced fields in the pharmaceutical industry. The "Made in China 2025" issued by the State Council includes biomedicine and high-performance medical devices as one of the top ten key areas. The company specializes in the research and development, production, and sales of biopharmaceuticals, ranking among the top in the biopharmaceutical industry, with strong competitiveness and high visibility. 2. Product competitiveness advantages The company is a leading producer and operator of protease and polysaccharide drugs, and is currently one of the few drug manufacturers in China that covers the entire heparin industry chain. The enzyme preparations mainly include pancreatic kininogenase series, compound digestive enzyme capsule II, and asparaginase series; The main varieties of polysaccharides are heparin sodium and small molecule heparin series, with a rich product line, reasonable product structure, and obvious comprehensive competitive advantages. They can effectively resist market risks and ensure sustained performance growth. 3. Advantages of Innovation Platform The company vigorously promotes technological innovation, introduces high-level talents from overseas to establish two joint venture research institutes, and sets up offshore drug research and development centers abroad. Based on this, the company establishes the "Changzhou Qianhong International Biomedical Innovation Drug Incubation Base". The company has made significant progress in the fields of biopharmaceutical innovation, such as gene recombination and targeted anti-cancer drugs. As of the end of the reporting period, the company has three innovative drugs entering phase II clinical trials, one innovative drug is about to enter phase II clinical trials, and multiple innovative drugs are in various stages of clinical research, which will provide strong core competitiveness for the company's future development. At the same time, the innovative drug industrialization project built by the company has been successfully completed and has been put into the production of clinical research samples for new drugs, laying a solid foundation for the transformation of innovative drug achievements under research. 4. Advantages of Technical Quality Management The company is a national high-tech enterprise that has developed core technologies such as modern molecular membrane ultrafiltration, molecular affinity chromatography, molecular structure chelation, virus inactivation, and integrated them into large-scale production of biochemical enzyme drugs and polysaccharide drugs. It has established an industrial production technology platform. The company has nearly 80000 square meters of high-level pharmaceutical production workshops and quality testing centers that comply with European and American GMP standards. It has a high-quality professional technical quality management team, a relatively complete production technology quality management system, and has been awarded the title of National, Provincial, and Municipal Drug Quality Integrity Demonstration Enterprise for many years. The internal control quality standards of multiple key products of the company have been upgraded to national drug quality standards; The main drugs exported have passed the GMP certification of the US FDA, EU COS, Germany, Japan, Australia and other countries. They also participate in the international standardization work of the US USP heparin sodium raw material, which has a certain competitive advantage among domestic and foreign peers. 5. Advantages of Talent Team Since its listing, the company (including its subsidiaries) has introduced a large number of young and talented individuals with high levels of education and specialization from both domestic and foreign sources. Currently, it has nearly 20 PhDs and over 80 masters, with more than 89% of the company's employees having a college degree or above. These individuals are widely distributed in the company's marketing, technology, and management teams, forming a stable talent pool system and laying a solid talent foundation for the company's future strategic development and business management needs. 6. Advantages of Marketing Model After years of accumulation, the company has established a diversified business model for domestic formulation sales, with self operated sales as the main body, investment promotion, and channels advancing simultaneously; Through technology and trade cooperation, multiple stable distribution networks for active pharmaceutical ingredients and formulations have been established in countries such as Europe, America, and Japan in foreign markets; It demonstrates the company's professional marketing team, diversified product structure and sales market competitiveness and advantages among peers. 7. Advantages of Qianhong Culture The company has established a modern enterprise management and governance system and standardized operating mechanism, and the operation and development of the enterprise continue to be stable; Qianhong has formed a unique culture of "integrity, pragmatism, and harmony", constructed a systematic corporate culture system, firmly established the awareness of "innovative development" in the hearts of cadres and employees, and recognized the values of "common development, co creation of prosperity". "I am proud of Qianhong, and Qianhong is proud of me" has become a trend, fully demonstrating the cultural connotation advantages of the company's sustainable and healthy development. The company adheres to the leadership of party building and cultural innovation, organically integrates party building work with daily operations, enhances the core competitiveness of the enterprise, and takes the Changzhou non-public enterprise party building work exhibition center as the battlefield to create a Qianhong characteristic party building brand. With Qianhong characteristic party building work as the starting point, the company strengthens the construction of its corporate culture management system.
Full description
Changzhou Qianhong Bio-pharma Co., Ltd. (stock name: “Qianhong Bio-pharma”, stock code: 002550) is a leading manufacturer and distributor of polysaccharide and protease drugs in the domestic biochemical pharmaceutical industry, a national high-tech enterprise and a key backbone enterprise of the national three-drug base, and has won the title of national and provincial and municipal drug quality integrity demonstration enterprise for many years. On February 18, 2011, it was successfully listed on the Shenzhen Stock Exchange. At present, it has four holding subsidiaries: ZonHon Biopharma Institute, Inc. (hereinafter referred to as ZonhonBio), Le Sun Pharmaceuticals Ltd. (hereinafter referred to as Le Sun), Qianhong Healthcare Co., Ltd. (hereinafter referred to as Qianhong Healthcare) and Hubei Runhong Biological Technology Co., Ltd. (hereinafter referred to as Hubei Runhong). Our main products include kallidinogenase series, heparin sodium and low molecular weight heparin series, compound digestive enzyme preparations and asparaginase series, which are pioneered in China. The production technology and quality level have reached the international and domestic advanced level. Multiple products have passed the quality certification organized by the governments of the United States, the European Union, Japan and other countries, respectively. The company has established a perfect domestic and foreign marketing network, products spread throughout more than twenty provinces and cities across the country, and exported to Europe, USA and Japan and other international markets. The company has established Changzhou Qianhong International Biomedical Innovative Drug Incubation Base, has an advanced R & D platform in the industry, has successively made significant progress in the research on multiple recombinant protein drugs and targeted anti-tumor drugs, and has entered human clinical trials with multiple Class I new drugs; at the same time, it has also undertaken a number of national, provincial and ministerial major scientific and technological R & D projects, providing a strong core competitiveness for the development and growth of the company. Looking forward to the future, the company will adhere to the development strategy of "focusing on the field of biomedicine, guiding core competitiveness with innovative drugs, and deepening the domestic preparation market and the export of high-value-added varieties" and strive to become one of the first-class competitive large-scale biomedical enterprises in China.